Cardiogen
Khavinson cardiac bioregulator
RUSSIAN RESEARCH · KHAVINSON SHORT PEPTIDE BIOREGULATOR
▓ 11 indexed citations across PubMed (10), ClinicalTrials.gov (1).
Citation breakdown by evidence tier
← weaker evidence · stronger evidence →
Tap any tier to jump to that section of the bibliography.
Mechanism of action
Tissue-specific gene expression modulation in cardiomyocytes
Researched effects
Cardiac tissue support; cardioprotection in animal models
Live evidence
Live signals refreshed daily. Current as of November 19, 2026.
Dosing reported in literature
Oral capsule 1-2x daily
Known concerns
Limited Western evidence; no regulatory approval
Top-ranked picks
10 pre-curated authoritative sources, ranked by journal tier and study weight.
- Prospective Evaluation of Strontium in Patients After CardioGen-82 PET MPI Scanning
- Rubidium-82 generator yield and efficiency for PET perfusion imaging: Comparison of two clinical systems.
- Limitations of Rb-82 weight-adjusted dosing accuracy at low doses.
- [Cardiomyopathy and ion channel diseases registry: the Szeged CardioGen Registry].
- An Analysis of 3 Common CardioGen-82 82Rb Infusion System Injection Methods and Their Impact on Clinical Volume and Image Counts.
- Update on CardioGen-82.
- Recall of CardioGen-82.
- [Peptidergic regulation of the expression of signal factors of fibroblast differentiation in the human prostate gland in cell aging].
- Tumor-modifying effect of cardiogen peptide on M-1 sarcoma in senescent rats.
- [The effect of the amino acids and cardiogen on the development of myocard tissue culture from young and old rats].
Full citation library
Year distribution
No references match — clear filters.
Trial Registrations (ClinicalTrials.gov)
1-
1.
Conditions: Radiation Exposure
Research Articles
10-
2.
Strontium-82/Rubidium-82 ( N = 515 sequential daily quality assurance (QA) reports from 9 CardioGen-82 At the start of clinical use, the system reported
-
3.
Weight-adjusted dosing is important to maintain accurate quantification for dynamic cardiac three-dimensional positron emission tomography (PET). However, the manufacturer of the only Food and Drug Administration approved rubidium-82 (Rb-82) generator (CardioGen-82, Bracco Diagnostics, Inc.) recommends recalibration after each change in dose which is inefficient in a busy clinical PET lab. The objective of this study was to evaluate the accuracy of Rb-82 dosing without this recalibration. After…
- 4.
-
5.
The tumor-modifying effect of cardiogen peptide was studied on rats with transplanted M-1 sarcoma. The level of apoptosis of tumor cells after cardiogen injections in all experimental groups was higher than in the control. The dose-dependent inhibition of M-1 sarcoma growth after injection of cardiogen was caused by the development of hemorrhagic necrosis and stimulation of tumor cell apoptosis. The parameters of proliferative activity indicate that inhibition of tumor growth was not caused by t…
-
6.
The Szeged cardiomyopathy and ion channel diseases registry aims to establish a representative disease-specific registry based on the recruitment of patients with different cardiomyopathies and ion channel diseases followed at the Cardiology Center, University of Szeged. The registry collects patient data on the main forms of primary cardiomyopathies (hypertrophic, dilated, restrictive, arrhythmogenic right ventricular, left ventricular non-compact, tako-tsubo cardiomyopathy) and ion channel dis…
-
7.
The effect of short peptides T-32, T-38 and cardiogen on the expression of signaling factors of the differentiation of human prostate's fibroblasts (PFM), which are the main cells of its microenvironment--protein CXCL12, WEDC1 and ghrelin in aging cultures has been studied. Confocal laser microscopy has demonstrated that all the investigated peptides possess the ability to actively enhance the expression of the above markers, whose synthesis significantly reduced in senescent cultures. It has be…
- 8.
-
9.
The synthetic peptides--cardiogen, bronchogen, prostamax and pancragen were used to investigate their effect on organotypic tissue culture of explants from heart, lungs, prostatic gland and pancreas of young (3-week old) and aged (18-month old) rats. The peptide effective concentration of 0.05 ng/ml showed a stimulating effect in appropriate tissue cultures as compared to the control explants in all groups of rats. So these bioregulatory peptides can be used in clinic practice for the stimulatio…
-
10.
The effect of 20 amino acids and the synthetic tetrapeptide cardiogen in concentration 10(-12) M was investigated in organotypic tissue culture on the cell proliferation and apoptosis development in myocard tissue explant in 3- and 24-months old rats. 7 of 20 amino acids stimulated the cell proliferation in the young rats. In the same time, only 2 amino acids were active in myocard culture from the old rats. The tetrapeptide cardiogen demonstrated the great stimulating effect on the proliferatio…
-
11.
In the wake of the Food and Drug Administration (FDA) recall, many clinics have had to reduce their examination volumes to meet the new generator volume usage requirements. This review tests 3 common infusion methods and how they affect patient dose, generator volume usage, image counts, and generator volume limits. Three common configurations of the (82)Rb infusion system settings--standard 50-mL, volume-limiting, and bolus methods--were tested to determine how they affect patient dose, generat…
Curated sources on file
3- 1.
- 2.
-
3.
Note: Primary literature on this peptide is published largely in Russian gerontology journals (Adv Gerontol, Bull Eksp Biol Med). English-indexed sources are limited to comprehensive Khavinson-laboratory reviews; entry confidence is correspondingly lower.